论文部分内容阅读
PURPOSE: To determine the safety and efficacy of verteporfin photodynamic ther apy (PDT) for the treatment of persistent choroidal neovascularization (CNV) pre viously treated with external beam radiotherapy (EBRT). DESIGN: Retrospective ca se series. METHODS: Verteporfin PDT was performed on 14 eyes of 13 patients with symptomatic leakage from CNV previously treated by EBRT. Principal outcome measures were: comparison of visual acuity at 12 months post -PDT with baseline and the recording of any ocular or systemic adverse events. RESULTS: At baseline, the mean logMAR (±SD) VA was 0.81 ±0.33, whereas at the 12-month point it was 0.89 ±0.43 (P=.326). At the 12-month examination 10 eye s had lost less than 3 lines of VA, and 8 eyes had lost less than 1.5 lines. Dur ing this time, there were 2.1 PDT treatment sessions per eye on average (range=1 to 4). There were no ocular or systemic adverse events recorded. CONCLUSIONS: T his short-term study shows that verteporfin PDT is safe after EBRT and may be o f benefit for recalcitrant CNV.
PURPOSE: To determine the safety and efficacy of verteporfin photodynamic ther apy (PDT) for the treatment of persistent choroidal neovascularization (CNV) previously treated with external beam radiotherapy (EBRT). DESIGN: Retrospective ca se series. METHODS: Verteporfin PDT was performed on 14 eyes of 13 patients with symptomatic leakage from CNV previously treated by EBRT. Principal outcome measures were: comparison of visual acuity at 12 months post-PDT with baseline and the recording of any ocular or systemic adverse events. RESULTS: At baseline, the mean logMAR (± SD) VA was 0.81 ± 0.33, while at the 12-month point it was 0.89 ± 0.43 (P = .326). At the 12-month examination 10 eye s had lost less than 3 lines of VA, and 8 eyes had lost less than 1.5 lines. Dur ing this time, there were 2.1 PDT treatment sessions per eye on average (range = 1 to 4). There were no ocular or systemic adverse events recorded. CONCLUSIONS: T his short-term study shows that verteporfin PDT is safe after EBRT and may be o f benefit for recalcitrant CNV.